非普拉宗，一种新型抗炎药。效能及胃肠道耐受性研究。
Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.
作者信息
Fletcher M R, Loebl W, Scott J T
出版信息
Ann Rheum Dis. 1975 Apr;34(2):190-4. doi: 10.1136/ard.34.2.190.
Abstract
Two studies are reported; a double-blind cross-over trial of feprazone 600 mg daily and aspirin 3.6 g daily in the treatment of rheumatoid arthritis, and an uncontrolled open study of gastrointestinal tolerance in twenty rheumatoid arthritis patients with known intolerance to other drugs. The first study showed that feprazone was significantly superior to aspirin in all the parameters tested. In the second study all twenty patients showed an improvement of their gastrointestinal symptoms, nineteen reporting no symptoms at all when taking the new preparation.
摘要
报告了两项研究
一项是关于每日服用600毫克非普拉宗和每日服用3.6克阿司匹林治疗类风湿性关节炎的双盲交叉试验，另一项是对20名已知对其他药物不耐受的类风湿性关节炎患者进行的胃肠道耐受性非对照开放研究。第一项研究表明，在所有测试参数中，非普拉宗显著优于阿司匹林。在第二项研究中，所有20名患者的胃肠道症状均有改善，19名患者在服用新制剂时报告完全没有症状。
相似文献
1
Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.非普拉宗，一种新型抗炎药。效能及胃肠道耐受性研究。
Ann Rheum Dis. 1975 Apr;34(2):190-4. doi: 10.1136/ard.34.2.190.
2
Gastrointestinal blood loss on phenylbutazone and feprazone.保泰松和非普拉宗引起的胃肠道失血。
Rheumatol Rehabil. 1976 May;15(2):108-11. doi: 10.1093/rheumatology/15.2.108.
3
Some studies of feprazone.一些关于非普拉宗的研究。
Rheumatol Rehabil. 1976 May;15(2):81-6. doi: 10.1093/rheumatology/15.2.81.
4
Feprazone compared with indomethacin in the management of rheumatoid arthritis.联苯乙酸与吲哚美辛治疗类风湿关节炎的比较。
Practitioner. 1975 Jul;215(1285):94-7.
5
Double-blind trial of feprazone and phenylbutazone in acute gout.非普拉宗与保泰松治疗急性痛风的双盲试验。
Curr Med Res Opin. 1980;6(7):445-8. doi: 10.1185/03007998009109465.
6
A double-blind trial of feprazone in osteoarthritis of the hip.非普拉宗治疗髋关节骨关节炎的双盲试验。
Curr Med Res Opin. 1977;4(9):665-9. doi: 10.1185/03007997709115289.
7
A trial of feprazone in ankylosing spondylitis.非普拉宗治疗强直性脊柱炎的试验。
Rheumatol Rehabil. 1977 Aug;16(3):158-61. doi: 10.1093/rheumatology/16.3.158.
8
[Results of an open study and a controlled comparative study of feprazone and naproxen in patients with rheumatoid arthritis or osteoarthrosis (author's transl)].非普拉宗与萘普生治疗类风湿性关节炎或骨关节炎患者的开放性研究及对照比较研究结果（作者译）
Wien Med Wochenschr. 1981 Dec 31;131(23-24):597-601.
9
A monitored-release study of methrazone in general practice.甲磺烟肼在全科医疗中的缓释研究。
J Int Med Res. 1980;8(4):276-82. doi: 10.1177/030006058000800406.
引用本文的文献
1
Feprazone Ameliorates TNF-α-Induced Loss of Aggrecan via Inhibition of the SOX-4/ADAMTS-5 Signaling Pathway.非普拉宗通过抑制SOX-4/ADAMTS-5信号通路改善肿瘤坏死因子-α诱导的聚集蛋白聚糖丢失。
ACS Omega. 2021 Mar 12;6(11):7638-7645. doi: 10.1021/acsomega.0c06212. eCollection 2021 Mar 23.
2
An objective measurement of change in morning stiffness.
Rheumatol Int. 1981;1(3):135-7. doi: 10.1007/BF00541258.
3
An analysis of the gastro-intestinal side-effects of non-steroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species.非甾体抗炎药胃肠道副作用分析，特别参考人与实验动物的对比研究
Rheumatol Int. 1982;2(1):1-10. doi: 10.1007/BF00541263.
4
Antirheumatic drugs: clinical pharmacology and therapeutic use.抗风湿药物：临床药理学与治疗应用。
Drugs. 1980 Dec;20(6):453-84. doi: 10.2165/00003495-198020060-00002.
5
Rectal administration of feprazone in healthy volunteers.在健康志愿者中进行非普拉宗的直肠给药。
Br J Clin Pharmacol. 1976 Apr;3(2):339-40. doi: 10.1111/j.1365-2125.1976.tb00616.x.
本文引用的文献
1
Long-term use of phenylbutazone in rheumatoid arthritis.苯基布他松在类风湿性关节炎中的长期应用。
Br Med J. 1960 Sep 17;2(5202):828-30. doi: 10.1136/bmj.2.5202.828.
2
DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.类风湿关节炎的诊断标准：美国风湿病协会委员会1958年修订版。
Ann Rheum Dis. 1959 Mar;18(1):49-51; French transl 51-2; Spanish transl 52-3.
3
The status of phenylbutazone (butazolidin) in the treatment of rheumatic disorders.保泰松（布他唑立丁）在风湿性疾病治疗中的地位。
Can Med Assoc J. 1958 Oct 15;79(8):634-8.
4
Clinical experience with phenylbutazone in 205 patients.205例患者使用保泰松的临床经验。
Am Pract Dig Treat. 1955 Dec;6(12):1865-9.
5
6
Ibuprofen in the management of osteoarthrosis of the hip.
Rheumatol Phys Med. 1972 May;11(6):281-6. doi: 10.1093/rheumatology/11.6.281.
7
Clinical study of a new anti-inflammatory drug: 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).一种新型抗炎药物：4-异戊烯基-1,2-二苯基-3,5-吡唑烷二酮（DA 2370）的临床研究
Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:265-8.
8
Clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in painful osteoarticular conditions.4-异戊烯基-1,2-二苯基-3,5-吡唑烷二酮（DA 2370）用于疼痛性骨关节炎病症的临床试验。
Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:262-5.
9
Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.4-异戊烯基-1,2-二苯基-3,5-吡唑烷二酮（DA 2370）用于类风湿性关节炎和强直性脊柱炎的临床及实验室评估
Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:253-8.
10
Analgesics and non-steroid anti-inflammatory agents in rheumatic disease.风湿性疾病中的镇痛药和非甾体抗炎药。
Practitioner. 1972 Jan;208(243):10-7.
Zotero 插件